Clinical and biochemical correction of a patient with neurodegenerative Mucopolysaccharidosis IIIA using hematopoietic stem cell gene therapy使用造血干细胞基因疗法对神经退行性黏多糖贮积症IIIA患者进行临床和生化纠正Molecular TherapyIF122026-09-250PRE
Failure of Allogeneic Transplant to Correct Sialidosis Despite Early Diagnosis and Full Donor Engraftment of Non-Carrier LeucocytesJOURNAL OF INHERITED METABOLIC DISEASEIF3.82026-01-050PRE
Clinical outcomes and sustained biochemical engraftment following ex-vivo autologous stem cell gene therapy for mucopolysaccharidosis type IIIAMOLECULAR GENETICS AND METABOLISMIF3.52024-02-013PRE
Sustained biochemical engraftment and early clinical outcomes following ex-vivo autologous stem cell gene therapy for mucopolysaccharidosis type IIIAMOLECULAR GENETICS AND METABOLISMIF3.52023-02-012PRE
Enzyme replacement therapy and hematopoietic stem cell transplant: a new paradigm of treatment in Wolman disease酶替代疗法和造血干细胞移植: Wolman病治疗的新范式ORPHANET JOURNAL OF RARE DISEASESIF3.52021-05-2124OAAI
Ex-vivo autologous stem cell gene therapy clinical trial for mucopolysaccharidosis type IIIA: Update on phase I/II clinical trialMOLECULAR GENETICS AND METABOLISMIF3.52021-02-012PREAI
Case report of the first patient treated with ex-vivo autologous haematopoietic stem cell gene therapy transplant in mucopolysaccharidosis type IIIAMOLECULAR GENETICS AND METABOLISMIF3.52020-02-013PREAI
Umbilical cord blood transplant is the preferred stem cell source in children with MPS IH (Hurler syndrome) undergoing hematopoietic stem cell transplantationMOLECULAR GENETICS AND METABOLISMIF3.52020-02-010PREAI